Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDV phase 2/3 dengue vaccine immunogenicity and safety trial in Japan
2024-000341-27Phase 3
- Sponsor
- Takeda
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dengue tetravalent vaccine, live, attenuated in dengue fever (3 arms), sponsored by Takeda. Primary endpoint: Percentage of seropositive subjects for each of the 4 dengue virus serotypes.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2024-000341-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000341-27.